Contact
searchSearch
HMP Global
Login

News

Three illustrated faces, one sad, one neutral, one happy, with a human hand picking up the happy face
News
Semaglutide May Improve Motivation in MDD, Small Trial Finds
05/04/2026
Brionna Mendoza
A randomized clinical trial published in JAMA Psychiatry found that oral semaglutide may improve effort-based decision-making in adults with major depressive disorder (MDD).
A randomized clinical trial published in JAMA Psychiatry found that oral semaglutide may improve effort-based decision-making in adults with major depressive disorder (MDD).
A randomized clinical trial...
05/04/2026
Psych Congress Network
A patient receives psychedelic-assisted therapy
News
Presidential Executive Order Seeks to Expand Psychedelic Access for Tough-To-Treat Mental Illnesses
04/29/2026
Brionna Mendoza
President Donald J. Trump signed an executive order titled “Accelerating Medical Treatments for Serious Mental Illness,” which aims to expand psychedelic therapy access for significant mental health issues, such as suicidality, major...
President Donald J. Trump signed an executive order titled “Accelerating Medical Treatments for Serious Mental Illness,” which aims to expand psychedelic therapy access for significant mental health issues, such as suicidality, major...
President Donald J. Trump signed...
04/29/2026
Psych Congress Network
a female soldier stands in front of a row of American flags
News
TMS Improves Residential Therapy Outcomes in Combat-Related PTSD
04/22/2026
Maria Mantas
Active navigated transcranial magnetic stimulation (TMS) added to intensive residential treatment was associated with greater reduction of symptoms in patients with combat-related posttraumatic stress disorder (PTSD) than sham TMS.
Active navigated transcranial magnetic stimulation (TMS) added to intensive residential treatment was associated with greater reduction of symptoms in patients with combat-related posttraumatic stress disorder (PTSD) than sham TMS.
Active navigated transcranial...
04/22/2026
Psych Congress Network
A person holds a cannabis joint in their hands
News
Cannabis Use in Youth Tied to Altered Cognitive Trajectories
04/21/2026
Brionna Mendoza
A large US longitudinal study published in Neuropsychopharmacology found that adolescents who initiated cannabis use showed flatter neurocognitive development over time than peers who did not use cannabis.
A large US longitudinal study published in Neuropsychopharmacology found that adolescents who initiated cannabis use showed flatter neurocognitive development over time than peers who did not use cannabis.
A large US longitudinal study...
04/21/2026
Psych Congress Network
A doctor sits at a table holding a pill bottle in one hand while filling out paperwork
News
Algorithm-Guided Treatment Improves Outcomes in Major Depressive Disorder
04/14/2026
Brionna Mendoza
A systematic review published in Frontiers in Psychiatry reports that algorithm-guided treatment (AGT) is generally associated with improved remission rates and more timely treatment modifications compared with treatment as usual (TAU).
A systematic review published in Frontiers in Psychiatry reports that algorithm-guided treatment (AGT) is generally associated with improved remission rates and more timely treatment modifications compared with treatment as usual (TAU).
A systematic review published in...
04/14/2026
Psych Congress Network
a person attempts to pick up a glass of water
News
Valbenazine Demonstrates Higher Persistence vs Deutetrabenazine in TD Patients
04/14/2026
Maria Mantas
Neurocrine Biosciences reported new real-world evidence demonstrating higher treatment persistence with valbenazine (Ingrezza) compared with deutetrabenazine (Austedo XR) among adults with tardive dyskinesia (TD).
Neurocrine Biosciences reported new real-world evidence demonstrating higher treatment persistence with valbenazine (Ingrezza) compared with deutetrabenazine (Austedo XR) among adults with tardive dyskinesia (TD).
Neurocrine Biosciences reported...
04/14/2026
Psych Congress Network
A boy's hand holding a pill that says ADHD
News
Open-Label Extension Trial Supports Long-Term Use of Viloxazine ER in Children and Adolescents
04/13/2026
A phase 3 open-label extension trial found viloxazine ER to be safe and effective for the long-term treatment of pediatric ADHD.
A phase 3 open-label extension trial found viloxazine ER to be safe and effective for the long-term treatment of pediatric ADHD.
A phase 3 open-label extension...
04/13/2026
Psych Congress Network
A teddy bear against a blue background wearing a mask and stethoscope.
News

ADHD Incidence Trends Accelerated After DSM-5 Changes and COVID-19 Disruptions
04/10/2026
Brionna Mendoza
Attention-deficit/hyperactivity disorder (ADHD) diagnosis rates in people younger than 30 years in British Columbia, Canada, rose steadily from 2003 to 2023 and appeared to accelerate after both DSM-5 implementation and the COVID-19 pandemic.
Attention-deficit/hyperactivity disorder (ADHD) diagnosis rates in people younger than 30 years in British Columbia, Canada, rose steadily from 2003 to 2023 and appeared to accelerate after both DSM-5 implementation and the COVID-19 pandemic.
Attention-deficit/hyperactivity...
04/10/2026
Psych Congress Network
A profile of a person split in half, one half teal and the other purple, with a swirl line over the head
News
Higher Risk of Premature Death Found in Bipolar II Disorder
04/07/2026
Brionna Mendoza
Bipolar II disorder (BD-II) is associated with significantly increased mortality, according to a large population-based cohort study published in JAMA Network Open.
Bipolar II disorder (BD-II) is associated with significantly increased mortality, according to a large population-based cohort study published in JAMA Network Open.
Bipolar II disorder (BD-II) is...
04/07/2026
Psych Congress Network
a man with depression looks out a window major depressive disorder
Research Summary
Psilocybin Produces Mixed Outcomes in Phase 2b MDD Study
04/01/2026
Brionna Mendoza
A Phase 2b randomized clinical trial found nonsignificant differences in response rate between psilocybin 25 mg, psilocybin 5 mg, and placebo with supporting psychotherapy in treatment-resistant major depressive disorder (MDD).
A Phase 2b randomized clinical trial found nonsignificant differences in response rate between psilocybin 25 mg, psilocybin 5 mg, and placebo with supporting psychotherapy in treatment-resistant major depressive disorder (MDD).
A Phase 2b randomized clinical...
04/01/2026
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, MSN, APRN, PMHNP-BC
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Insights
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use